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Abstract
Individualized treatment rules (ITRs) tailor treatments according to individual patient char-
acteristics. They can significantly improve patient care and are thus becoming increasingly
popular. The data collected during randomized clinical trials are often used to estimate the
optimal ITRs. However, these trials are generally expensive to run, and, moreover, they are
not designed to efficiently estimate ITRs. In this paper, we propose a cost-effective estima-
tion method from an active learning perspective. In particular, our method recruits only
the “most informative” patients (in terms of learning the optimal ITRs) from an ongoing
clinical trial. Simulation studies and real-data examples show that our active clinical trial
method significantly improves on competing methods. We derive risk bounds and show that
they support these observed empirical advantages.
Key words: Active Learning, Clinical Trial, Individualized Treatment Rule, Personalized
Medicine, Risk Bound.
1 Introduction
It is widely recognized that different patients respond differently to the same treatment.
Recent advances in personalized medicine have the potential to improve treatment decisions
in clinical practice by tailoring the clinical interventions to the patient characteristics. These
characteristics include demographics, medical histories, and genetic or genomic information
(Hamburg and Collins, 2010). It is anticipated that these new developments in personalized
medicine may salvage some failed medications, which is especially important given the low
overall success rate recently observed in clinical trials (DiMasi et al., 2010).
The success of personalized medicine is contingent on the correct identification of the
best treatments for each individual. One research direction is subgroup analysis, where
the patients are grouped based on the estimated individual-level treatment differences (Cai
et al., 2011; Foster et al., 2011). Alternatively, vigorous research has focused on finding
optimal treatment regimens, which yield the greatest benefit overall for the whole population.
Some methods involve fitting a regression model for the response, and recommending the
treatment achieving the best prediction (Qian and Murphy, 2011). Instead, Zhao et al.
(2012) explore the optimal individualized therapies from a classification perspective (see
also Zhang et al. (2012)). All these methods are implemented using data from randomized
clinical trials (RCTs). However, traditional RCTs are primarily designed to confirm the
efficacy of new treatments; they do not generate comprehensive personalized therapy rules
in an efficient manner. Consequently, post-mining data from RCTs is not ideal for finding
optimal treatment strategies (Cui et al., 2002; Lagakos, 2006). RCTs generally require a
large sample size to demonstrate the efficacy of a candidate treatment, and they can be
expensive to run because of the need to treat and monitor a large number of subjects. In
addition, RCTs waste trial resources on subjects who experience treatment effects that are
relatively large. Therefore, it would be desirable to design cost-effective clinical trials for
personalized medicine. Such trials would highlight individual differences in responses and
take advantage of continuing advances revealed in the trial (Singer, 2005).
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We propose an active learning framework for conducting clinical trials, called active clin-
ical trials. In these trials, patients are judiciously recruited so that the optimal ITRs can be
learned with fewer patients being randomized; this is a cost-effective method. Unlike tradi-
tional RCTs, we will exclude the patients for whom the benefit from one of the treatments
is clearly observed, thus concentrating on those for whom the difference is less pronounced.
Specifically, within the classification framework (Zhao et al., 2012), we first construct “confi-
dence intervals” for the optimal decision boundary using the data accumulated so far based
on either a frequentist or Bayesian approach. We then selectively enroll the patients whose
optimal treatments are hard to determine, i.e., their benefit differences from the different
treatments are “small,” based on the above confidence intervals. Those patients are viewed
as the most informative for the purpose of learning the optimal ITRs, and thus they are
recruited for randomizations at the next stage. As will be seen in the empirical and theo-
retical analysis, the real-time selection of the right patients indeed improves the chance of
discovering optimal ITRs with a drastically reduced sample size and cost.
Our work is related to the topic of budgeted learning (Madani et al., 2004; Raghavan
et al., 2006; Deng et al., 2007) in computer science. These work aim to find the most accurate
classifier subject to a fixed budget. The main difference is that the responses for the subjects
are assumed to be known, and the covariate information is required. Our work in the clinical
trial setting sequentially applies treatments to selected subjects and then observes their
responses. Another related topic in computer science is the “multi-armed bandit problem”
(Robbins, 1952), where resources are allocated among multiple arms given a fixed budget.
One tries to maximize the cumulative rewards over all allocations. This perspective is also
taken in response-adaptive trials (Rosenberger and Lachin, 1993; Hu and Rosenberger, 2006),
which allocate more patients to the better treatment based on the available patient responses.
Thus, such trials can be viewed as exploitative, since most of them adopt myopic strategies
by exploiting the current best arm. Our method is more exploratory, exploring patients close
to the decision boundary to learn better individualized treatment rules for future practice.
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Some adaptive enrichment designs (Wang et al., 2009; Simon and Simon, 2013) are similar in
that they allow the eligibility criteria to be updated during the trial. However, our primary
goal is to construct informative and favorable ITRs rather than to confirm the efficacy of
one treatment over another. Our method is also different from adaptive randomization
procedures, which primarily aim to place more subjects onto the treatment arm that is more
promising (Rosenberger et al., 2012). Deng et al. (2011b) proposed a minimax bandit model
for clinical trials that carefully distributes the trial resources, with the same objective as our
method. However, they specify subpopulations in advance, and the optimal treatments are
learned for each subpopulation. The resulting ITRs may not be ideal if the subpopulations
are not formed correctly.
In Section 2, we introduce a general methodology for conducting active clinical trials,
along with methods for constructing optimal ITRs using the accumulated data. In Section
3, we discuss the theoretical properties of our approach by providing a finite sample upper
bound on the difference in the expected outcome under the estimated ITR and the optimal
ITR. In Section 4, we conduct extensive simulation studies to examine the empirical per-
formance and also compare the results with those of Deng et al. (2011b). Two real data
examples are presented in Section 5, and Section 7 provides a discussion. The technical
details are presented in the Appendix and the Supplementary Materials.
2 Methodology
2.1 Optimal Individual Treatment Rule
In this section, we discuss a probabilistic framework for studying the optimal ITRs that
is similar to that of Qian and Murphy (2011) and Zhao et al. (2012). Let (X,A,R) be a
random triple with a joint distribution P . Here, X ∈ Rp denotes the patient’s baseline
covariates with marginal distribution Π, A is a binary treatment assignment taking values
in {−1, 1}, and R stands for the treatment outcome (a larger value of R corresponds to a
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better outcome). An ITR D(·) is defined as a function from the covariate space Rp into the
treatment space {−1, 1}.
We use the value function, denoted as V (D), to measure the quality of D, which is a
marginal mean outcome representing the overall population mean were all patients to receive
treatment according to D. Our goal is to identify the optimal ITR that yields the maximum
V (D). For any ITR D, let PD be the distribution of (X,A,R) when A = D(X), and let ED
be the corresponding expectation. The value function V (D) = ED(R). Qian and Murphy
(2011) show that V (D) can be expressed as
V (D) = E
[
RI(A = D(X))
pi(A;X)
]
, (2.1)
where E denotes the expectation w.r.t. the joint distribution P , I(·) is an indicator function,
and pi(a;X) is the conditional probability P (A = a|X) for a ∈ {−1, 1}. For simplicity, we
assume a pure randomization scheme with equal probability for different assignments, i.e.,
pi(a;X) = 1/2, throughout the paper.
Let D∗ denote the optimal treatment rule that maximizes V (D). By rewriting V (D) as
V (D) = E
(
E[RI(D(X) = 1)|A = 1, X] + E[RI(D(X) = −1)|A = −1, X]
)
, we obtain
D∗(x) = sign{f ∗(x)}, (2.2)
where f ∗(x) := E[R|A = 1, X = x] − E[R|A = −1, X = x] is called the contrast function.
The optimal decision boundary is just the level set {x ∈ Rp : f ∗(x) = 0}. As can be seen, the
overall benefit will be maximized if the patients satisfying f ∗(x) ≥ 0 receive the alternative
treatment (treatment 1), and the others receive standard care (treatment -1). Hence, the
decision is tailored according to the patient’s characteristics represented by X.
To estimate the optimal ITR D∗ from the data {X(i), A(i), R(i)}ni=1, usually collected
from a clinical trial, one can fit a parametric or nonparametric regression model for E[R|A =
a,X = x] (equivalently, f ∗(x)), and then estimate the optimal ITR by plugging the fitted
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model into (2.2). Alternatively, we can replace the problem of maximizing (2.1) by min-
imizing a weighted classification error E [RI(A 6= D(X))/pi(A;X)]. In this case, existing
classification techniques, e.g., support vector machines, can be adapted to estimate D∗(x);
see Zhao et al. (2012) for more details. All of the above methods take the whole (random-
ized) clinical trial data as an input, and thus they have no influence on the data collection
process. They belong to the class of passive learning methods, also called batch learning. In
clinical trials, the patient recruiting process is usually long, and the treatment and monitor-
ing process can be extremely expensive. With a limited budget and a fixed sample size, we
should wisely allocate the resources, i.e., decide who to recruit, in order to learn the optimal
ITRs at a lower cost. This motivates us to propose active clinical trials that can identify the
optimal ITRs with a significantly reduced cost.
2.2 Active Clinical Trials
The active learning (AL) approach in the classification literature is shown to produce accu-
rate classifiers with a significantly reduced number of label requests; see Balcan et al. (2008),
Dasgupta et al. (2007), Castro and Nowak (2008), Koltchinskii (2010), Hanneke (2011), and
Minsker (2012). Recall that the estimation of ITRs can be thought of as a classification
problem. For example, a patient with a small outcome given the assigned treatment is po-
tentially misclassified. We use AL techniques to select the “most informative” patients based
on a given pool of prognostic variables, and then we randomize only the patients with these
“informative” characteristics. The intuition behind this patient-selection process is simple:
if we have confidence that certain patients will benefit from a particular treatment, we should
not recruit them into the study since they are not likely to contribute to the estimation of
ITRs. However, it is hard to determine the optimal treatment, i.e., the sign of f ∗(x), for the
patients whose baseline variables are “close” to the optimal decision boundary. As will be
seen from the empirical and theoretical analysis, patients with such features are more “in-
formative” in the sense that their outcomes after randomization provide more insight into
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the optimal ITRs (to be applied to future patients). Moreover, since patients will not be
randomized if we have confidence in the treatment they should receive, they are less likely
to be exposed to ineffective medications.
We assume that there is no delay in observing the outcome. For S ⊂ supp(Π) and a
function f : Rp 7→ R, let f |S : S 7→ R be the restriction of f onto S, and define ‖f‖∞,S =
‖f |S‖∞ := sup
x∈S
|f(x)|. Given δ > 0, set
F∞,S(f, δ) := {g : S 7→ R : ‖g − f‖∞,S ≤ δ}
as a δ-band around f on S. A precise description is given in Algorithm 1. Here, we introduce
the important notion of an active set (Minsker, 2012), which underlies the majority of active
learning algorithms. At step k of our Algorithm 1, the active set ASk is defined to be the
set of baseline variables for which the best treatment is not yet known. The active set is
characterized by the confidence interval, i.e., x belongs to the active set if and only if the
confidence interval for f ∗(x) contains both positive and negative elements; Figures 1 and
2 below illustrate this. The approximation of ASk using a regular set actk is discussed in
Appendix A.1.
−1.5 −1 −0.5 0 0.5 1 1.5 2 2.5
−2
−1.5
−1
−0.5
0
0.5
1
1.5
2
2.5
3
3.5
 
 
Contrast function f ∗
Estimator fˆ of f ∗
Confidence band for f ∗
Figure 1: Confidence band for the con-
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Figure 2: X(1) belongs to the active set;
X(2) does not.
In practice, it is not necessary to evaluate the active sets explicitly at each step. Instead,
at step k, we repeat the following two steps until we reach the number of patients that can
be randomized:
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Algorithm 1: Active Clinical Trials for Personalized Medicine
input : Sample size limit N ; confidence α
output: D̂ := sign(f̂)
1 k = 0, act0 := supp(Π);
Set the initial N0 := 2b
√
Nc, and LB := N −N0;
for i = 1 to N0 do
Recruit X(i,0) from Π;
Randomize X(i,0) to treatment A(i,0) = 1 or −1 with equal probability;
Observe R(i,0);
end
2 Construct the estimator f̂0(x) of f∗ from S0 =
{(
X(i,0), A(i,0), R(i,0)
)}N0
i=1
;
while LB > 0 do
3 F̂k :=
{
f : f |actk ∈ F∞,actk (f̂k; 32 δk), f |supp(Π)\actk ≡ f̂k−1|supp(Π)\actk
}
/* δk: confidence band size
*/;
4 k := k + 1;
ASk :=
{
x ∈ supp(Π) : ∃f1, f2 ∈ F̂k−1, sign(f1(x)) 6= sign(f2(x))
}
/* active set */;
Approximate ASk with a regular set actk;
5 if actk ∩ supp(Π) = ∅ then
break
end
else
Nk = 2Nk−1;
for i = 1 to bNk ·Π(actk)c do
Recruit X(i,k) from the active set Π̂k := Πactk (dx);
Randomize X(i,k) to treatment A(i,k) = 1 or −1 with equal probability;
Observe R(i,k), Sk :=
{(
X(i,k), A(i,k), R(i,k)
)
, i ≤ bNk ·Π(actk)c
}
;
end
Construct the estimator f̂k(·) of f∗ based on Sk;
LB := LB − bNk ·Π(actk)c;
f̂ := f̂k /* keeping track of the most recent estimator */;
end
end
1. Recruit a group of new patients with baseline variables X(i,k), i = 1, . . . , Nk.
2. Let f̂i,k(X
(i,k)) be the estimator of f ∗(X(i,k)) based on Sk and Ii,k = [f̂k(X(i,k)) −
δ(X(i,k)), f̂k(X
(i,k)) + δ(X(i,k))] be the confidence interval, where Sk is defined in Algo-
rithm 1 and represents the available sample in the kth step.
(a) If 0 /∈ Ii,k: drop the patient from the study.
(b) If 0 ∈ Ii,k: randomize the patient, record the outcomeR, and add (X(i,k), A(i,k), R(i,k))
to the current sample.
The above procedure gives a data set containing “the most informative” observations for
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predicting the optimal treatment. For every new patient, this data set will be used to predict
the treatment rule based on that individual’s baseline variables. At each iteration, we must
specify an estimator of the contrast function and the corresponding confidence interval. In
the next section, we will propose two construction methods based on kernel estimation and
Gaussian process regression, respectively. We remark that the empirical performance of our
method is essentially controlled by the confidence level that we set. This level also determines
the rejection ratio, e.g., N = 100 out of 140 total iterations in simulation Scenario 1 of Section
4.
2.3 Confidence Interval Construction
2.3.1 Kernel Smoothing Approach
Let K be a smooth kernel function (with bandwidth hn) satisfying Assumption (A2) in
Section 3. Define Khn(x0−X) := K((x0−X)/hn)/hpn. Let ηj(x) := E[R|A = j,X = x], j =
±1, be the conditional expectation of R given A and X. Given n observations from P , we
propose the estimators η̂j(·;hn) for j = ±1, and the plug-in estimator f̂(·;hn) of the contrast
function f ∗(·). At any fixed point x0,
η̂j(x0;hn) =
n∑
i=1
Khn(x0 −X(i))I(A(i) = j)R(i)
n∑
i=1
Khn(x0 −X(i))I(A(i) = j)
, j = ±1, (2.3)
f̂(x0;hn) = η̂1(x0;hn)− η̂−1(x0;hn).
Here, hn = hn(x0) is an adaptive bandwidth parameter varying with x0. We need to choose
a proper hn(x0), which controls the local amount of data near x0, to optimally balance the
estimation bias and variance; see Appendix A.2.2 for the technical details.
Assuming that both η1 and η−1 are Lipschitz continuous with Lipschitz constants bounded
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by L, we define
hn,j(x0) = inf
h > 0 : L2h2 ≥
C1(K,P )
n∑
i=1
I {‖x0 −X(i)‖2 ≤ h} I{A(i) = j}
 , j = ±1,
where C1(K,P ) is a constant depending on the kernel K and distribution P , and ‖ · ‖2 is
the usual Euclidean norm. Set
hn(x0) := max (hn,1(x0), hn,−1(x0)) . (2.4)
This choice mimics the usual “bias-variance tradeoff”: indeed, the bias of η̂j(x0;h) is bounded
by the order of Lh, while
( n∑
i=1
I
{‖x0 −X(i)‖2 ≤ h} I{A(i) = j})−1 plays the role of the
variance parameter. Based on the above choice of hn(x0), i.e., (2.4), we define the radius of
the confidence interval to be
δ(x0) := t · Lhn(x0),
where t controls the coverage probability. The display above depends on the unknown
constants C1(K,P ) that must be chosen before running the algorithm. Given a certain
confidence level, we recommend selecting the “confidence parameter” t by reverting the
coverage probability error that decays exponentially fast with t; see Corollary A.1.
Remark 1. We are aware that the proposed kernel methods are unfortunately affected by
the “curse of dimensionality.” However, our theoretical analysis reveals that the empirical
performance of our kernel estimate essentially depends on the “intrinsic dimension” d of the
support of the marginal distribution Π (see Assumption (A3) in Section 3), which might be
much lower than the ambient dimension p. The concept of the intrinsic dimension originated
in geometry and was later introduced to statistics, e.g., Allard et al. (2012). It characterizes
a low-dimensional representation embedded in a high-dimensional space. For example, when
the data are linear, we may use principal component analysis to identify the subspace that
9
contains the data. The number of important components is the intrinsic dimension d, which
can be significantly smaller than the total number of covariates p. In practice, we follow the
local singular value decomposition method, suggested in Little et al. (2009), to determine the
intrinsic dimension.
2.3.2 Gaussian Process Regression Approach
The new method presented in this section is particularly well suited for applications since
it is completely data-driven and does not require us to specify any unknown parameters
in advance; its performance is demonstrated in Section 4. However, the price is that we
must assume that the conditional distribution of the outcome R given (A,X) is Gaussian.
In other words, if an individual with baseline variables X receives treatment A = j, we
assume that the outcome satisfies R = ηj(X) + ε for j = ±1, where ε ∼ N(0, σ2). In this
situation, we take a Bayesian approach by imposing a Gaussian process prior (defined by the
mean m(·) and covariance k(·, ·)) on functions η1(·) and η−1(·); see Chapter 2 of Rasmussen
and Williams (2006). For simplicity, the mean function m(·) is set to be identically zero
throughout this paper.
As before, the confidence interval of the contrast function builds upon those of η1(·) and
η−1(·). Hence, we start from the inference procedure for η1(·). Let {(X(i), R(i))}n1i=1 be the
observations corresponding to the individuals who received treatment 1. The covariance
function of the Gaussian process prior is set as a slight variant of the squared exponential
kernel: given x = (x1, . . . , xp) and x
′ = (x′1, . . . , x
′
p) ∈ Rp,
kγ(x, x
′) = γ0 exp
(
−
p∑
l=1
(xl − x′l)2
2γ2l
)
for some positive γ0, . . . , γp. Let Kγ be a p × p matrix with entries (Kγ)l1,l2 = kγ(Xl1 , Xl2),
l1, l2 = 1, . . . , p. Under the Gaussian error assumption, the marginal distribution of the
vector R = (R(1), . . . , R(n1))T given X = (X(1), . . . , X(n1)) is a multivariate Gaussian with
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mean 0 and covariance matrix KR := Kγ + σ
2Ip, where Ip is a p × p identity matrix. The
“optimal” value Γ∗ := (γ∗0 , . . . , γ
∗
p , σ
2
∗) of the parameter Γ = (γ0, . . . , γp, σ
2) is then “learned”
from the data by finding a local maximum of the marginal log-likelihood
log p(R|X,Γ) := −1
2
RTK−1R R−
1
2
log detKR − n1
2
log 2pi
with respect to (γ0, . . . , γp, σ
2); see Section 5.4.1 in Rasmussen and Williams (2006) for more
details. Therefore, the Gaussian process regression is a global method that can automatically
select the bandwidth by maximizing the data likelihood. This is in contrast with the previous
kernel method where the bandwidth is selected locally; see Equation (2.4) above.
We next construct the confidence interval based on the posterior distribution of η1(·)
with the optimal Γ∗. Given a new observation with the baseline variable x0, the value of
η1(x0) is estimated by the posterior mean, denoted η̂1(x0), i.e.,
η̂1(x0) := kΓ∗(x0,X)K
−1
R R,
where kΓ∗(x, x
′) := γ∗0 exp(−
p∑
l=1
(xl − x′l)2/2(γ∗l )2) for x, x′ ∈ Rp, and
kΓ∗(x0,X) = (kΓ∗(x0, X
(1)), . . . , kΓ∗(x0, X
(n1))).
The variance of the posterior distribution is given by
σ̂21(x0) := kΓ∗(x0, x0)− kΓ∗(x0,X)K−1R kΓ∗(x0,X)T .
The square root of the posterior variance naturally controls the length of the confidence
interval for η1(x0). For example, setting δ1(x0) := 3σ̂1(x0) gives the confidence interval for
η1(x0) of posterior probability > 99% (note that this may not correspond to the frequentist
coverage).
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Define η̂−1(x0) and the associated δ−1(x0) analogously. We thus obtain a confidence
interval with the center f̂(x0) := η̂1(x0)− η̂−1(x0) and the radius δ(x0) := δ1(x0) + δ−1(x0).
The numerical implementation of this Bayesian inference procedure can easily be performed
with the gpml Matlab toolbox (Rasmussen and Nickisch, 2010).
3 Theoretical Analysis
In this section, we focus our theoretical analysis on the kernel smoothing approach. The
frequentist property of the credible set for the nonparametric Bayesian method has not been
well developed. Hence, a theoretical analysis of the Gaussian process regression method is
beyond the scope of this paper.
For simplicity, we suppose that the marginal distribution Π of the baseline variable vector
X is known. Note that Algorithm 1 does not need to know or estimate Π explicitly, and
this assumption is only for the theoretical analysis. In addition, we assume the following
conditions on the kernel K : Rp 7→ R and the distribution Π:
(A0) Both η1(x) := E[R|A = 1, X = x] and η−1(x) := E[R|A = −1, X = x] are Lipschitz
continuous on Rp with Lipschitz constants bounded by L.
(A1) The random variable |R| is bounded by 0 < M <∞ a.s.
(A2) K(x) is a nonnegative, compactly supported, Lipschitz-continuous function with a
Lipschitz constant LK . Moreover, K(x) ≥ `KI{‖x‖2 ≤ 1} for some `K > 0.
(A3) The “intrinsic dimension” of supp(Π) is equal to d for some integer d ≤ p, and Π is
equivalent to the uniform distribution over its support; see Appendix A.1 for a more
precise statement.
(A4) Margin condition: there exist K2 = K2(Π), γ = γ(Π) > 0 such that for all t > 0
Π (x : |f ∗(x)| ≤ t) ≤ K2tγ.
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Assumption (A3) says that over a “nice” set, Π is close to the uniform distribution;
see condition (A.1) in the Appendix. The intrinsic dimension d is crucial here: in many
applications, p is large but d is small (see Remark 1). Note that the rate in our main result,
Theorem 3.1, depends on d but not on p. Assumption (A4) is an analogue of the well-known
margin condition (Tsybakov, 2004), which is commonly used to characterize the complexity
of a binary classification problem. Larger values of γ mean that the two treatment effects
are less likely to be similar, yet in nontrivial examples, γ ∈ [0, d]. In particular, as indicated
in Proposition 3.4 in Audibert and Tsybakov (2007), for a smooth contrast function f ∗(x),
γ ∈ [0, d] unless f ∗(x) does not cross 0 at any point in the interior of supp(Π), i.e., all the
patients benefit from one treatment. Note that our analysis does not require γ to be known
in advance.
We are now ready to present the (finite-sample) performance guarantee for our method.
Theorem 3.1. Let hk = [{log(N/α) + d log(Nk)}/Nk]1/(d+2), k = 0, . . . , L, where L is the
total number of iterations in Algorithm 1. Set the associated δk = 4Chk, where C is a
constant specified in Lemma A.1. With probability greater than 1 − α, the estimator D̂ of
D∗ returned by Algorithm 1 satisfies
∣∣∣V (D̂)− V (D∗)∣∣∣ ≤ C˜N− 1+γ2+d−γ (log(N/α))θ ,
where N is the number of randomized subjects, θ = (4+2d−γ)(1+γ)
(2+d)(2+d−γ) , and C˜ is a constant that
depends on the kernel K and distribution Π.
It is worth noting that when γ is large (say, close to d), the rate of Theorem 3.1 is “almost”
dimension-free. We also remark that the rate of Theorem 3.1 can not be uniformly improved
by any active learning technique, as shown in Minsker (2012). Qian and Murphy (2011) used
a parametric modeling approach, i.e., they fitted an L1-penalized regression model to estimate
the optimal ITRs, and they obtained a rate of (logN/N)(1+γ)/(2+γ) with an appropriate choice
of tuning parameter. However, their model could be misspecified in practice. In contrast,
13
our method is nonparametric with possibly minimal model assumptions.
4 Simulation Studies
In this section, we assess the empirical performance of the active clinical trial method. Let
X = (X1, X2, . . . , Xp), where X1, . . . , Xp are independent of each other. The distribution of
X varies according to different scenarios detailed below. The treatment A is generated from
{−1, 1} with equal probability. The response R is generated from N(Q0(X,A), 1), where
Q0(X,A) = m0(X) + T0(X,A).
Here, T0(X,A) is the interaction between the treatment and the baseline variables. In what
follows, U [a, b] stands for the uniform distribution on the interval [a, b] ⊂ R. Consider four
scenarios for T0(X,A):
1. Xl ∼ U [−1, 1], l = 1, 2,m0(X) = 1 + 2X1 +X2, T0(X,A) = 0.5(1−X1 −X2)A.
2. Xl ∼ U [−1, 1], l = 1, 2,m0(X) = 1 + 2X1 +X2, T0(X,A) = 1/2 + (1−X21 −X22 )(X21 +
X22 − 1)A.
3. p = 3,m0(X) = 1 + 2X1 +X2−X3, T0(X,A) = 1.5(X1X2(1 +X3))A, where X1, X2, X3
are on the sphere generated as follows. Let X˜1, . . . , X˜3 ∼ U [−1, 1], and
Xl =
X˜l√∑3
l=1 X˜
2
l
I
( 3∑
l=1
X˜2l ≤ 1
)
, l = 1, 2, 3.
4. p = 8,m0(X) = 1 + 2X1 + X2 −X3, T0(X) = 0.2(
∑
l is evenXl −
∑
l is oddXl)A, where
X1, . . . , X8 have uniform distribution U [−1, 1].
It can be seen that the optimal ITR for Scenario 1 is linear, i.e., D∗(X) = sign(1 −
X1 −X2). The optimal ITR for Scenario 2 is nonlinear, with D∗(X) = I(0.3 ≤ X21 + X22 ≤
14
1.7). Scenario 3 represents the case where the data are supported on the manifold, i.e., a
two-dimensional sphere in R3. The treatment effect in Scenario 3 is highly nonlinear with
D∗(X) = sign(X1X2(1 + X3)). Scenario 4 has a relatively high dimensional covariate, i.e.,
8, with a linear treatment effect.
We apply the active clinical trial outlined in Algorithm 1. We implemented both the ker-
nel method in Section 2.3.1, denoted AL-BV, and the Gaussian process regression method
in Section 2.3.2, denoted AL-GP. We used the gpml Matlab toolbox (Rasmussen and Nick-
isch, 2010) in the latter method. The active clinical trial proceeds by selectively recruiting
subjects whose differential treatment effects are smaller than a threshold, i.e., Steps 3–4
of Algorithm 1. This iterative procedure screens out a certain number of subjects, whose
optimal treatments can be determined with high confidence, and retains the remaining N
subjects for estimating the optimal ITR. The active learning algorithm proposed in Deng
et al. (2011a) serves as a comparison. The designed trial therein focuses on simple ITRs that
utilize a small number of subpopulation categories to personalize the treatment. In par-
ticular, they assume the subpopulations are known a priori. Throughout the clinical trial,
they sequentially select the (subpopulation, treatment) pair so as to minimize the maximal
error of selecting a suboptimal treatment. For all the scenarios, we form four subgroups by
dichotomizing X1 and X2 at 0. We use MINMAXPICS, the algorithm name in their paper,
to denote this method.
In addition, we compare with two passive learning approaches: the outcome weighted
learning (OWL) method (Zhao et al., 2012) and the ordinary least square (OLS) method.
Both methods recruit subjects upon arrival in the clinical trial and estimate the optimal
ITR using the collected data after the trial ends. N subjects are randomly selected for both
methods. In the OWL method, using the available data, we minimize the target function
Pn [Rφ(Af(X))/pi(A;X)] + λn‖f‖22, where φ(t) = max(1 − t, 0) is the hinge loss, Pn is the
empirical measure, and λn is a tuning parameter controlling the amount of penalization.
We consider a nonlinear functional space for the ITRs, and a Gaussian kernel is used in
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the implementation. The optimal ITR is estimated via D̂(x) = sign(f̂(X)), where f̂(x) are
the minimizers of the above objective function. In the OLS method, we first regress R on
(X,A,XA), and then estimate the optimal ITR by finding the treatment that yields a larger
predicted outcome for each individual.
The initial sample size N0 is fixed at 50, while the additional sample size N − N0 is
50, 100, 200, 300, 400, 500, or 800. To evaluate the empirical performance, we generated a
testing dataset of sample size 10000, mimicking a large pool of future subjects. The estimated
ITRs D̂(X) using the different methods are validated on this large testing set. Since the
main effect is invariant across different ITRs, we can calculate the average excess value
AEV (D∗, D̂) as
AEV (D∗, D̂) =
1
n
n∑
i=1
[T0(X
(i), D∗)− T0(X(i), D̂)], n = 10000
where the empirical average is taken over the validation set. This quantity directly reflects the
expected clinical benefits for future subjects treated according to D̂(X), with a smaller value
indicating a better treatment decision. We repeat the process 1000 times and average the
resulting values over all the runs. In Figure 6, we plot log{AEV (D∗, D̂)} against log(N−N0),
where D̂ was obtained using each method. The log-scale is used to give a better display of
the polynomial convergence rates in the different methods.
In all the scenarios, our active clinical trials perform uniformly better than OWL. In Sce-
nario 1, the treatment effect is linear, which indicates that OLS is the best possible method.
However, AL-GP has comparable performance, especially when the sample size is large. The
performance of AL-BV also improves with N . When the treatment effect is nonlinear, as
in Scenarios 2 and 3, the strength of active learning is clearly demonstrated. Both methods
initially perform better for small sample sizes and then converge much faster as the sample
size grows. In contrast, the values of the estimated ITRs from the other two methods do not
converge (Scenario 3) or do not converge to the optimal value (Scenario 2). In Scenario 4, the
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number of covariates is increased to eight. This places severe difficulties on the kernel esti-
mation because of the curse of dimensionality. However, with the linear treatment effect, the
AL-GP results are satisfactory compared with those of OLS. The MINIMAXPICS algorithm
performs the best in Scenario 3, where the subpopulations are correctly defined in advance.
When the prespecification of the subpopulations is incorrect, each subpopulation contains
both patients who benefit from treatment 1 and patients who benefit from treatment -1.
In this case, the constructed ITRs are not ideal, even with large sample sizes. In general,
we believe that active learning methods provide robust results for various treatment mech-
anisms, which are usually unknown in practice. We presented some additional simulation
results in the supplementary materials, where we investigated scenarios with biomarkers of
normal distribution, and conducted several sensitivity analyses.
5 Real Data Analysis
5.1 Nefazodone–CBASP Clinical Trial
We apply the proposed active learning methods to analyze the data from the Nefazodone–
CBASP clinical trial (Keller et al., 2000). The randomized trial was conducted to compare
the efficacy of three treatments for nonpsychotic chronic major depressive disorder (MDD),
namely Nefazodone, cognitive behavioral-analysis system of psychotherapy (CBASP), or a
combination of Nefazodone and CBASP. CBASP requires twice-weekly on-site visits to the
clinic, and thus imposes a significant burden on patients compared with Nefazodone alone.
Hence, we compare Nefazodone with the combination treatment, and investigate whether
CBASP is necessary for all patients. We perform a complete case analysis. The score on
the 24-item Hamilton rating scale for depression (HRSD) was the primary outcome, with
higher scores indicating more severe depression. Data from 441 patients were available, with
218 patients randomized to Nefazodone and 223 to the combined treatment group. We
consider three covariates for tailoring the treatment: the baseline HRSD scores, the alcohol
17
Figure 3: Excess values (log scale). Initial size was set to 50.
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dependence, and the HAMA somatic anxiety scores. The latter two covariates were selected
by Gunter et al. (2007) as important variables for optimal treatment decision making.
All the patients are used for the OLS and OWL analysis. To mimic an active clinical
trial, we first randomly select 50 patients as the initial dataset. We then sequentially ex-
amine the remaining patients, and drop those who do not satisfy the selection criteria. The
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recruitment stops once an additional 300 patients are enrolled, or all the patients have been
examined. The eligible patients are included in the dataset, assuming that they have been
randomized in an active clinical trial. The treatments they are randomized to in this hypo-
thetical active clinical trial are the actual treatments they received in the completed trial.
In particular, 289 and 350 patients were used to construct the optimal ITRs using AL-BV
and AL-GP respectively. The estimated ITRs from the different methods were applied to
the whole data set to calculate the average HRSD scores due to the ITRs, with smaller
values being preferable. Here, the “average HRSD scores due to the ITRs” are defined to
be Pn[{R˜I(A = D(X)}/pi(A)]/Pn[{I(A = D(X)}/pi(A)], where R˜ denotes the HRSD scores
and pi(A) is the probability of being assigned treatment A. AL-BV recommends combination
therapy for 299 patients, giving an average HRSD score of 8.86. AL-GP recommends this
therapy for 386 patients, giving an average HRSD score of 9.72. OLS and OWL recommend
this therapy for all the patients, yielding a higher score of 10.89. Hence, the treatment rules
produced by the active clinical trials not only lead to a higher overall benefit, but also reduce
the time and monetary commitments for the patients.
We then used a five-fold cross-validation analysis to avoid potential overfitting. The data
set was partitioned into five subsets. Four of the five subsets were used as training data
to construct the optimal ITR, and the remaining subset was used as the validation set to
evaluate the estimated rule. In the training subset, we applied both active learning and
passive learning methods, i.e., OLS and OWL, to construct the optimal ITRs. The initial
sample size was set to 50 for the active learning methods. The number of additional recruited
patients was 20, 30, . . . , 200; these were adaptively selected from the rest of the training
samples. For the passive learning methods, we randomly chose 70, 80, . . . , 250 patients from
the training data and conducted the estimation. The process was repeated 200 times, and we
recorded the average cross-validated values for each sample size. The results are presented in
Figure 4. The active learning methods initially lead to higher HRSD scores, but they catch
up and continue to improve as the sample size grows. In particular, we can see that the
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HRSD scores from our methods decrease faster than those of the other methods do. After
the additional sample size reaches 120, with the total sample size at 170, the ITR identified
by AL-BV yields the lowest score, and this value can be further improved with larger sample
sizes.
Figure 4: Mean cross-validated HRSD scores (the lower the better) against additional sample
sizes. The initial sample size was set to 50.
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5.2 Twelve-step Intervention on Stimulant Drug Use
These data come from a randomized clinical trial that aims to evaluate the effectiveness
of 8-week group intervention plus individual 12-step facilitative intervention for reducing
stimulant drug use (Donovan et al., 2013). Individuals with stimulant-use disorders were
randomly assigned to treatment as usual (TAU) or to TAU integrated with Stimulant Abuser
Groups to Engage in 12-step (STAGE-12) intervention.
The primary outcome of interest is the number of days of self-reported stimulant drug use
over the three- to six-month post-randomization period, where a smaller value is preferable.
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We use seven baseline variables to evaluate the patients and to construct the optimal ITR:
age, average number of days per month of self-reported stimulant drug use in the three
months prior to randomization, baseline alcohol use, drug use, employment status, medical
status, and psychiatric status composite scores on the addiction severity index (ASI), where
the ASI composite score, ranging from 0 (no endorsement of any problems) to 1 (maximal
endorsement of all problems), is usually taken as an indication of problem severity; it is
perceived to guide the treatment decision (McGahan et al., 1986).
After removing the missing data, we have 305 participants in total. We evaluated the
different methods on the whole data set, with the initial sample size set to 50 and the
additional sample size set to 200. AL-BV and AL-GP assigned 123 and 90 patients to the
STAGE-12 group, with expected outcomes of 11.3 and 12 respectively. OLS and OWL gave
overall averages of 11.8 and 12.7 days. We also calculated the cross-validated number of
days of drug use over the three- to six-month post-randomization period. Since the outcome
was count data, with considerable zero-inflation, overdispersion, and a nonlinear trend, we
anticipated that the active learning method using a bias-variance tradeoff for the estimation
would lead to the best results. Indeed, as shown in Figure 5, AL-BV outperforms the other
methods with a fast overall decreasing trend. While the Gaussian assumption is severely
violated in this example, AL-GP still improves with sample size. We note that OLS and
OWL do not improve noticeably as the sample size grows.
6 Sample Size Consideration
In order to design a future study, it is important to plan ahead a sample size, which is
sufficient to guarantee that we will obtain an ITR very close to the optimal one using the
proposed active clinical trial. Here, we provide a data-driven method that gives a preliminary
assessment of the required sample size. Further work is warranted to derive the sample size
formula for such an exploratory trial. Let V0 be an average patient outcome based on the
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Figure 5: Mean cross-validated outcomes (number of days of self-reported stimulant drug
use over the three- to six-month post-randomization period, the lower the better) against
additional sample sizes. The initial sample size was set to 50.
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standard care. Our goal is to determine a minimal sample size N∗ such that: (1) the power
to reject the hypothesis V (D∗) = V0 is at least 1 − β when V (D∗) ≥ (1 + ρ)V0; and (2)
Pr(|V (DˆN∗)− V (D∗)| ≤ ) ≥ 1− α (Laber et al., 2015), where , α, and ρ are prespecified
constants and DˆN is the resulting estimator based on N samples from the active clinical trial.
Since we have constructed a non-asymptotic error bound for |V (DˆN)−V (D∗)| in terms of the
sample size N in Theorem 3.1, we suggest to obtain N∗ by inverting the above error bound
such that Pr(|V (DˆN∗)−V (D∗)| ≤ min(ρV0, )) ≥ 1−α. By doing so, we are able to provide
finite sample evidence that the optimal individualized treatment rule yields a larger average
benefit than the standard care, and, moreover, the average benefit of the estimated rule is
approximately optimal. The constant γ ∈ [0, d] will be determined based on prior knowledge,
or can be set to a range of values to examine the resulting sample sizes. The unknown
constant C˜ can be determined via simulations. Given d, γ, θ and C˜, the required sample size
N∗, such that with probability greater than 1 − α, |V (DˆN∗) − V (D∗)| ≤ min(ρV0, ), can
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be found by setting C˜N∗−
1+γ
2+d−γ (log(N∗/α))θ = min(ρV0, ). The required sample sizes vary
by the allocated initial sample size N0. Therefore, our sample size calculation is conditional
on a specified N0. We will illustrate the proposed strategy by designing a future study to
explore the optimal ITRs for patients with MDD. The Nefazodone-CBASP clinical trial is
used as the basis for planning.
Consider two treatment options, Nefazodone only versus the combined treatment. The
average HRSD score in the combined treatment group is 10.96. It is desirable to develop
an ITR that can at least reduce the expected HRSD score that would be achieved by 15%
with probability greater than 80%, i.e., ρV0 ≈ 1.7 and α = 0.2. We will use three tailoring
variables with d = 3.. To determine C˜, we adopt a bootstrap method. We will bootstrap
the data, a total of 441 patients, 10000 times. An active clinical trial, with 50 initial and
100 additional patients, will be implemented with each bootstrapped sample to estimate
the optimal ITR. The average HRSD score under each estimated ITR will be recorded. We
denote these scores as Vˆ B1 , . . . , Vˆ
B
10000. Let k
∗ = argmink=1,...,10000Vˆ
B
k . Vˆ
B
k∗ will be used as an
estimate of V (D∗). Denote the 80 percentile of |Vˆ Bk − Vˆ Bk∗ |, k 6= k∗, k = 1, . . . , 10000 as D̂iff .
C˜ can be obtained using C˜ = N
1+γ
2+d−γ (log(N/α))−θ × D̂iff , where N = 150 and α = 0.2.
We will assess different γ’s with γ = 0.5, 1, 1.5, 2, 2.5 and 3, which lead to different θ’s and
different estimates of C˜. Using the outlined strategy, we suggest to plan the sample size for
the future study according to Table 1.
 γ = 0.5 γ = 1 γ = 1.5 γ = 2 γ = 2.5
1.7 165 160 155 155 150
1.6 215 190 175 165 160
1.5 280 225 200 180 170
Table 1: Planned sample size for different combinations of (γ, ).
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7 Discussion
In this paper, we propose an active clinical trial with the goal of constructing favorable ITRs
at a minimal cost. This new paradigm is distinct from the standard clinical trial framework
that is designed for treatment evaluation. Along with the new designs, we also present new
analysis and inference tools that are often practically useful and theoretically efficient. Two
methods are presented to construct the confidence interval in the algorithm. The kernel
smoothing method is better in the situation where a few important tailoring variables are
known a priori. However, due to the curse of dimensionality, it cannot handle a covariate
space of moderate to high dimension. The Gaussian process regression approach performs
better in this situation. However, the kernel smoothing method does not assume a specific
underlying distribution of the outcomes, whereas the Gaussian process regression approach
requires the outcome to follow a Gaussian distribution, which may not be appropriate for
discrete outcomes. Since the goal of the proposed trial is to explore the optimal treatment
rules, it is a learning stage. The results should be further validated in a confirmatory trial.
In practice, we may also want to include individuals who would be known to benefit from
the treatment. Instead of dropping certain patients whose confidence interval for the contrast
function does not contain 0, we can enroll all patients with different priority (quantified by
probability). Specifically, we can prioritize those patients, whose confidence interval of the
contrast function contains 0, by assigning larger probabilities, while enrolling patients, whose
confidence interval for the contrast function does not contain 0, with lower probabilities.
Under this more flexible framework, individuals who benefit from the treatment are also
included in the trial such that the marginal treatment effects can be investigated. In addition,
when there is a small difference between two medications, treatment choice will likely depend
on other considerations such as cost, side effects and etc. Our framework can take into
account those factors that can be quantified. By allowing a ratio of the cost per treatment
relative to the cost of a worse disease outcome, say δ, which reflects the patients’ tolerance
of treatment burden relative to tolerance of the disease burden (Vickers et al., 2007; Huang
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and Laber, 2014), we maximize V (D) − δP (A = 1). The optimal rule is instead given by
D∗(x) = sign{f ∗(x)−δ}. In this case, the active clinical trial will enroll patients from whom
the value of f ∗(x) is close to δ, since these patients are close to the decision boundary and
thus most informative.
We next discuss two directions for future research. First, our method can easily be
extended to incorporate multi-category treatments, where patients are recruited based on
the minimum differential treatment effect of all the pairwise comparisons. For continuous
treatments, one possibility is to discretize the continuous treatment into different percentiles
and then apply the extended method for multi-category treatments. Second, in this paper,
we assume that the outcomes of the previous patients have been observed before we enroll
the next patient. In fact, the proposed active clinical trials can be conducted with delayed
responses, provided the required estimates (for the contrast function) can be updated as data
become available, i.e., some responses can be collected during the study period. We can also
update the estimates after groups of responses instead of individual responses. There have
been some recent developments on handling the problem of delayed outcomes in phase I–II
trials, for example, by treating them as missing values and applying imputation strategies
(Jin et al., 2014). We would like to explore such options in the future. There are two other
interesting extensions that we are pursuing: (i) a more general contrast function that can
accommodate a high-dimensional or discrete covariate; (ii) a dynamic treatment regime for
a sequence of treatment rules (Murphy, 2003; Robins, 2004).
A Technical Proofs
A.1 Intrinsic dimension of supp(Π)
We explain the meaning of “intrinsic dimension” introduced in Assumption (A3) here. We
say that supp(Π) possesses a tree decomposition T = {Ti,j, i ≥ 1, j = 1 . . . J(i)} if
1. T1,1 = supp(Π), and {Ti,j}J(i)j=1 forms a disjoint partition of supp(Π) for all i ≥ 1.
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2. Nested partition: ∀i ≥ 2, j = 1, . . . , J(i), there exists a unique 1 ≤ k ≤ J(i − 1) such
that Ti,j ⊂ Ti−1,k;
3. Bounded diameter: for all i ≥ 1, 1 ≤ j ≤ J(i),
diam(Ti,j) := sup
x,y∈Ti,j
‖x− y‖2 ≤ K12−i
for some K1 = K1(Π).
4. Regularity: for any i ≥ 1, 1 ≤ j ≤ J(i) and 0 < r ≤ 2−i the following holds: there
exists a 1 ≤ d ≤ p (d is the intrinsic dimension) such that for all x ∈ Ti,j,
c1r
d ≤ Π(B(x, r) ∩ Ti,j) ≤ c2rd (A.1)
for some 0 < c1(Π) ≤ c2(Π) < ∞ which are independent of i, j. Here, B(x, r) is the
Euclidean ball of radius r centered at x.
A simple example that gives a good intuition to the tree decomposition is the uniform
distribution over the unit cube in Rp. In this case, the tree decomposition is given by
partitioning the unit cube into dyadic cubes and d = p. If supp(Π) is contained in a proper
subspace W of Rp, then d ≤ dim(W ).
Let Bi be the sigma-algebra generated by the collection of sets {Ti,j, j = 1, . . . , J(i)} (a
partition of supp(Π) on the level i). A regular approximation of ASk in Algorithm 1 is given
by actk :=
⋂{
A : A ∈ Bmk−1 , A ⊃ ASk
}
.
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A.2 Properties of Kernel Estimate
A.2.1 Preliminaries
For a measurable set S ⊂ supp(Π), define ΠS(dx) := Π(dx|x ∈ S) as the conditional
distribution on S, and set
Qh(x|S) :=
∫
Rp
Kh (x− y) dΠS(y).
Since Π is assumed to be known, we can directly compute Qh(x|S) now. Accordingly, we
modify the original kernel estimate for ηj, i.e., (2.3), as follows: let {(X(i), A(i), R(i)), i =
1 . . . N} be an i.i.d. sample from the conditional joint distribution of (X,A,R) given that
X ∈ S, and set
η̂j(x;h, S) =
1
N
N∑
i=1
R(i)I{A(i) = j}Kh
(
x−X(i))
Qh(x|S)P (A(i) = j) , j = ±1, (A.2)
f̂(x;h, S) = η̂1(x;h, S)− η̂−1(x;h, S).
We will discuss properties of these estimators in below.
Let h > 0, S ∈ Bj and h ≤ 2−j, and define
Qh,m(x|S) :=
∫
Rp
‖x− y‖m2 Kh (x− y) dΠS(y) (A.3)
We next study the upper and lower bounds of Qh,m(x|S) based on Assumptions (A1)-(A4).
Since K is bounded and compactly supported, there exists R = RK > 0 such that K(x) ≤
‖K‖∞I{x ∈ B(0, RK)}. Let F > 0 be a large enough constant, namely, F d ≥ 2c2/c1. Recall
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that c1, c2 are defined in (A.1). Note that Assumption (A2) implies the following:
Qh,m(x|S) ≥ `K
∫
B(x,h)∩S
‖x− y‖m2 dΠS(y)
≥ `K (h/F )m
 ∫
B(x,h)∩S
dΠS(y)−
∫
B(x,h/F )∩S
dΠS(y)

≥ `K (h/F )m
(
c1h
d − c2(h/F )d
)
Π(S)
≥ 1
2Fm
`Kc1
hd+m
Π(S)
:= c3
hd+m
Π(S)
, (A.4)
and
Qh,m(x|S) ≤‖K‖∞
∫
B(x,RKh)∩A
‖x− y‖m2 dΠS(y) ≤ ‖K‖∞Rm+dK c2
hd+m
Π(S)
:= c4
hd+m
Π(S)
. (A.5)
In what follows, we will set Qh(x|S) := Qh,0(x) for brevity.
A.2.2 Some bounds for the kernel estimators
In this subsection, we derive basic concentration inequalities for the kernel estimators of
ηj(x) = E[R|A = j,X = x], j = ±1 restricted to S, i.e., η̂j(x;h, S) defined in (A.2). The
proof of the results can be found in supplementary materials.
Lemma A.1. For all t > 0 satisfying t+ d2 log(1/h) ≤ nhd, with probability ≥ 1− 2e−t,
sup
x∈supp(Π)∩S
|η̂j(x;h)− ηj(x)| ≤ C
(
h+
√
Π(S)(t+ d2 log(1/h))
nhd
)
,
where C = C(M, c1, c2, L, LK , ‖K‖∞, `K , RK) is a constant.
The following Corollary is immediate:
Corollary A.1. Set hn := {Π(S)(t+ d log(n/Π(S)))/n}1/(d+2). Then, under assumptions
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of Lemma A.1, with probability ≥ 1− 4e−t,
sup
x∈supp(Π)∩S
|f̂(x;hn)− f ∗(x)| ≤ 4Chn,
where constant C is the same as in Lemma A.1.
A.3 Proof of Theorem 3.1
A.3.1 Comparison inequality
Our Lemma A.2 below illustrates the connection between the risk V (D̂)−V (D∗) of a treat-
ment rule D̂(x) = sign(f̂(x)) and the sup-norm ‖f̂ − f ∗‖∞,supp(Π).
Lemma A.2. Under the margin assumption (A4),
V (D̂)− V (D∗) ≤ C(γ)‖(f̂ − f ∗)I
{
sign(f̂) 6= sign(f ∗)
}
‖1+γ∞,supp(Π).
Proof. It is easy to see that V (D̂)− V (D∗) = 2E
(
|f ∗(X)|I{D̂(X) 6= D∗(X)}
)
. The rest of
the argument repeats Lemma 5.1 in Audibert and Tsybakov (2007).
A.3.2 Main proof
Our main goal is to control the size of the set actk defined by Algorithm 1. In turn, these
bounds depend on the size of the confidence bands for f ∗(x) (denoted by δk). Suppose L ≤ N
is the number of iterations performed by the algorithm before termination.
Let Nactk := bNk ·Π(actk)c be the number of labels requested on the k-th iteration of the
algorithm. We first claim that the following bounds hold uniformly for all 1 ≤ k ≤ L with
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probability at least 1− α:
‖f ∗ − f̂k‖∞,actk ≤ C1
(
log(N/α) + d log(Nk)
Nk
)1/(d+2)
,
Π(actk) ≤ C2
(
log(N/α) + d log(Nk−1)
Nk−1
)γ/(d+2)
, (A.6)
where Cj = Cj(M, c1, c2, L, LK , ‖K‖∞, `K , RK , γ), j = 1, 2. This claim will be proved later.
Let E be the event of probability ≥ 1 − α on which both inequalities of (A.6) hold,
and assume that it occurs. Second inequality of (A.6) implies, together with the fact that
Nk = 2Nk−1 by definition, that the number of randomized subjects on each step 1 ≤ k ≤ L
satisfies
Nactk = bNkΠ(actk)c ≤ 2N
2+d−γ
2+d
k−1 (log(N/α) + d log(Nk−1))
γ/(d+2)
with probability ≥ 1−α. If N is the maximum number of randomized subjects the algorithm
is allowed to request, then
N ≤
L∑
k=0
Nactk ≤ 2 (log(N/α) + d log(NL))γ/(d+2)
L∑
k=0
N
2+d−γ
2+d
k ≤
C3(γ, d) (log(N/α) + d log(NL))
γ/(d+2) N
2+d−γ
2+d
L ,
and one easily deduces that on the last iteration L we have
NL ≥ c(γ,Π, d)
(
N
log(N/α)
) 2+d
2+d−γ
. (A.7)
Recall that NL is defined in Algorithm 1.
To obtain the risk bound of the theorem from (A.7), we apply Lemma A.2:
V (D̂)− V (D∗) ≤ C(γ)
∥∥∥(f̂L − f ∗) · I {sign(f̂L) 6= D∗}∥∥∥1+γ∞,supp(Π) . (A.8)
Since
{
sign(f̂L) 6= D∗
}
⊆ actL whenever bounds (A.6) hold, it remains to estimate ‖f̂L −
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f ∗‖∞,actL . Recalling the first inequality of (A.6) once again (for k = L), we get
‖(f̂L − f ∗)‖∞,actL ≤ C1
(
log(N/α) + d log(NL)
NL
)1/(d+2)
≤ C˜N− 12+d−γ (log(N/α))q ,
where q = 4+2d−γ
(2+d)(2+d−γ) , which together with (A.8) yields the final result.
It remains to show both inequalities of (A.6). We start with the bound on ‖f̂k−f ∗‖∞,actk .
First, note that by construction, for every k ≥ 1 the samples (X(i,k), A(i,k), R(i,k)), i =
1 . . . bNkΠ(actk)c are conditionally independent given the data
⋃k−1
i=1 Si collected on steps
1, . . . , k−1, with conditional distribution of X(i,k) being Πactk . Thus we can apply Corollary
A.1 conditionally on
⋃k−1
i=1 Si with t = log
4N
α
to get that with probability ≥ 1− α/N ,
‖f̂k − f ∗‖∞,actk ≤ 4C
(
log α
4N
+ d log(bNkΠ(actk)c/Π(actk))
bNkΠ(actk)c/Π(actk)
)1/(d+2)
≤ 8Chk.
It remains to integrate the bound with respect to the distribution of
⋃k−1
i=1 Si:
P
(
‖f̂k − f ∗‖∞,actk ≥ 8Chk
)
= EP
(
‖f̂k − f ∗‖∞,actk ≥ 8Chk
∣∣ k−1⋃
i=1
Si
)
≤ α
N
.
The union bound over all 1 ≤ k ≤ L ≤ N gives the result.
Finally, we will prove the second inequality of (A.6), the bound for the size of the active
sets actk. This is the place where assumption (A3) on the tree decomposition and margin
assumption (A4) play the key role. To obtain the bound, we will compare two estimators
of f ∗: the first is the kernel estimator f̂k constructed by the Algorithm 1 on step k, and
the second is the piecewise-constant estimator f¯k with similar approximation properties to
f̂k. Namely, f¯k is the L2(Π) - projection of f
∗ on the linear space of piecewise-constant
functions of the form g(x) =
J(mk)∑
j=1
αjI{Tmk,j}(x), αj ∈ R. Recall that Ti,j is defined in the
tree decomposition of Section A.1. As a result, we will be able to relate the “active sets”
associated to these estimators, taking advantage of the fact that the active set associated to
f¯k is always a union of the sets from a collection {Tmk,j, j = 1 . . . J(mk)}.
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Let E1 be the event of probability ≥ 1− α on which ‖f̂k − f ∗‖∞,actk ≤ δk for any k ≥ 0,
where δk = 4Chk. Assume that E1 occurs.
The following inclusions hold (for the definition of ASk+1, see Algorithm 1):
{x : |f ∗(x)| < δk/2} ⊆ ASk+1 ⊆ {x : |f ∗(x)| < 5δk/2} . (A.9)
Indeed,
|f ∗(x)| < δk/2 =⇒ |f̂k(x)| < δk/2 + |f ∗(x)− f̂k(x)| < 3
2
δk =⇒ x ∈ ASk+1
and
x ∈ ASk+1 =⇒ |f̂k(x)| < 3
2
δk =⇒ |f ∗(x)| < 5
2
δk.
For all x ∈ Tmk,j, set f¯k(x) := 1Π(Tmk,j)
∫
Tmk,j
f ∗(y)dΠ(y), and note that
|f ∗(x)− f¯k(x)| ≤ 1
Π(Tmk,j)
∫
Tmk,j
|f ∗(y)− f ∗(x)|dΠ(y) ≤ 2L
Π(Tmk,j)
∫
Tmk,j
|x− y|dΠ(y) ≤
2L diam(Tmk,j) ≤ 2LK12−mk ≤ 4LK1hk,
where the last two inequalities follow from part 3 of assumption (A3) given in Appendix A.1,
and from the definition of mk. Define τk := max (5δk, 4LK1hk) ≤ C5δk, F¯k+1 := {f :
|f(x)− f¯k(x)| ≤ (3/2)τk, ∀x ∈ actk} to be the band of size (3/2)τk around f¯k, and
A¯k+1 :=
{
x ∈ actk : ∃f1, f2 ∈ F¯k+1, sign(f1(x)) 6= sign(f2(x))
}
.
By a reasoning similar to above, we have the inclusions
{x : |f ∗(x)| < τk/2} ⊆ A¯k+1 ⊆ {x : |f ∗(x)| < 5τk/2} . (A.10)
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Moreover, by the definition of τk, we have the inequality 5δk/2 ≤ τk/2. Hence (A.9,A.10)
imply that ASk+1 ⊆ A¯k+1. It remains to note that
1. A¯k+1 is the union of the sets from a collection {Tmk,j, j = 1 . . . J(mk)}, hence A¯k+1 ⊇
actk+1;
2. By (A.10) and assumption (A4),
Π(actk+1) ≤ Π(A¯k+1) ≤ Π({x : |f ∗(x)| < 5τk/2}) ≤ K2(5τk/2)γ ≤ C6δγk ,
hence proving the claim.
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Supplementary Materials for “Active Clinical Trials for
Personalized Medicine”
S.1 Additional simulation results
S.1.1 Simulation setups with normal biomarkers
In this section, we first present two additional examples where biomarkers have normal dis-
tributions (Scenarios 5 and 6). Particularly, X1 and X2 are generated according to N(0, 1).
Treatments A1, A2 are randomly generated from {−1, 1} with equal probability 0.5. Out-
comes R are generated as follows.
5. R ∼ N(1 + 2X1 + 0.5(X21 − 0.25)A, 1);
6. R ∼ N(1 + 2X21 +X2 + 2(log(|X2|) +
√|X1| − 1)A, 1).
The results are presented in Figure 6. The outcome models are fairly complex in both
scenarios. Hence the results from OLS are unsatisfactory. We prespecify 4 subgroups, with
X1 and X2 dichotomized at 0, to implement the approach proposed in Deng et al. (2011a).
Since these pre-specified subgroups are incorrect to inform the optimal treatment rule, the
ITRs estimated by their approach are not consistent for the optimal. Both active learn-
ing methods show competitive performances in both scenarios. Kernel approach performs
slightly worse than the Gaussian process regression. This phenomenon is anticipated since
the bounded support assumption required in theoretical guarantee is violated.
S.1.2 Sensitivity analysis
In this section, we conduct a thorough sensitivity analysis to investigate whether the perfor-
mances of the proposed methods depend on the choices of initial sample size N0. Basically,
any number that is “significantly smaller” than the total allocated budget should lead to the
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Figure 6: Excess values (log scale). Initial size was set at 50.
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same theoretical asymptotic behavior. Indeed, we vary N0 from 30, 50 to 80 and find that
the results are insensitive to the choice. We present the sensitivity analyses for Gaussian
process regression method in Figure 7. The results for kernel approach are similar (data not
shown).
We also investigate how the confidence level δ(x0) in the step of Algorithm 1 affects the
performance of the algorithm. The confidence level δ(x0) is controlled by the parameter
t, where δ(x0) = tLhn(x0). We vary t over the set {0.3, 0.5, 0.8, 1}, and implicitly assume
L = 1. The results presented in Figure 8 clearly show that algorithm performances are
robust to the choice of the confidence parameter.
S.1.3 Doubly-robust estimator
The individualized treatment rule can also be constructed via a doubly robust augmented
inverse probability weighted estimator. Here we examine the performance of such an esti-
mator, which is used for estimation and participant inclusion in the active clinical trial. A
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Figure 7: Excess values (log scale) with different initial sizes in Gaussian process regression
method. ‘N0 flexible’ means N0 = 2b
√
nc.
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doubly robust representation for the value function V (D) is
V AIPWE,m(D) , E
[
RI {A = D(X)}
pim(A;X)
− I {A = D(X)} − pi
m{D(X);X}
pim{D(X);X} Q
m{X,D(X)}
]
,
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Figure 8: Excess values (log scale) with different confidence parameters in kernel method.
Initial size was set at 50.
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where pim(a;x) denotes a working model for P (A = a|X = x) and Qm(x, a) denotes a working
model for E(R|X = x,A = a). It can be shown that V AIPWE,m(D) = V (D) when either
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pim(a;x) or Qm(x, a) is correctly specified (Zhang et al., 2012). Denote
Wma = I(A = a)
R−Qm(X, a)
pim(a;X)
+Qm(X, a).
The optimal treatment rule maximizing V AIPWE,m(D) is
D∗(x) = sign{E(Wm1 |X = x)− E(Wm−1|X = x)}.
Within the framework of active clinical trial, patients for whom the difference between
E(Wma |X = x), a = ±1, is small are more likely to get enrolled, since they are closer to
the decision boundary. In the implementation, pim(a;x) = 1/2 is known. We can plug
in the estimated E(R|X = x,A = a) to estimate E(Wma |X = x). Subsequently, the es-
timated E(Wm1 |X = x) − E(Wm−1|X = x) can be used to select enrolled patients. We
examine the performance of active clinical trial based on a doubly robust estimator, where
E(R|X = x,A = a) are estimated using either kernel regression method (‘AL-BV-DR (KR)’)
or a simple linear regression with (X,A,XA) as predictors (‘AL-BV-DR (LR)’). Results for
Scenarios 1-6 are shown in Figure 9. These results are relatively insensitive to the choices
of working models for Qm(x, a). However, the performances of the doubly robust estimators
vary across different situations. This might be due to a larger variability from using the
doubly robust estimators with more estimation required. It will be of interest to further
investigate the properties of active clinical trial via doubly robust estimators.
S.2 Additional theoretical results
Proof of Lemma A.1
We prove Lemma A.1 here. Below is the usual “bias-variance” decomposition
‖η̂j(x;h)− ηj(x)‖∞ ≤ ‖η̂j(x;h)− Eη̂j(x;h)‖∞ + ‖ηj(x)− Eη̂j(x;h)‖∞.
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Figure 9: Excess values (log scale), ’AL-BV’ denotes the approach using the kernel smoothing
estimator. ’AL-BV-DR (KR)’ denotes the approach based on a doubly robust estimator
using kernel regression for Qm(x, a) and ’AL-BV-DR (LR)’ denotes the approach based on
a doubly robust estimator using linear regression for Qm(x, a).
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We start with a bound on the bias term. Note that for any x ∈ S ∩ supp(Π), Eη̂j(x;h) =
1
Qh(x|S)
∫
K
(
x−y
h
)
ηj(y)dΠS(y), hence
|η̂j(x;h)− Eη̂j(x;h)| =
∣∣∣∣ 1Qh(x|S)
∫
(η(x)− η(y))K
(
x− y
h
)
dΠ(y)
∣∣∣∣ ≤
L
Qh(x|S)
∫
‖x− y‖2K
(
x− y
h
)
dΠS(y) = L
Qh,1(x|S)
Qh(x|S) ≤ L
c4
c3
h, (A.11)
where c3, c4 are defined in Section A.3.1. Recall that Qh,1(x|S) is defined in (A.3) with
Qh,1(x|S) :=
∫
Rp
‖x− y‖2Kh (x− y) dΠS(y).
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Next, we will bound the stochastic term. Given ε > 0, let {x(k)}N(ε)k=1 be the minimal ε-net
on S ∩ supp(Π), so that for any y ∈ S ∩ supp(Π) there exists 1 ≤ k(y) ≤ N(ε) such that
‖y − x(k(y))‖2 ≤ ε. Set ε := hd+1. Then
sup
y∈S∩supp(Π)
|η̂j(y;h)− ηj(y)| = (A.12)
sup
y∈S∩supp(Π)
|η̂j(y;h)− η̂j(x(k(y));h) + η̂j(x(k(y));h)− ηj(x(k(y))) + ηj(x(k(y)))− ηj(y)| ≤
max
1≤i≤N(ε)
|η̂j(x(i);h)− ηj(x(i))|+ sup
‖x−y‖2≤ε
|ηj(x)− ηj(y)|+ sup
‖x−y‖2≤ε
|η̂j(x;h)− η̂j(y;h)|.
Lipschitz condition on ηj implies that
sup
‖x−y‖2≤hd+1
|ηj(x)− ηj(y)| ≤ Lhd+1
and, since |R| ≤M almost surely and K has Lipschitz constant LK ,
sup
‖x−y‖2≤hd+1
|η̂j(x;h)− η̂j(y;h)| ≤ MLKΠ(S)
c3hd
ε =
MLKΠ(S)
c3
h.
Fix 1 ≤ i ≤ N(ε). We will apply the Bernstein’s inequality (e.g., Lemma 2.2.9 in van der
Vaart and Wellner (1996)) to estimate |η̂j(xi;h)− Eη̂j(xi;h)|. Our assumptions imply that
for all 1 ≤ i ≤ N ,
∣∣∣∣∣R(i)I{A(i) = j} Kh
(
x−X(i))
Qh(x|S)P (A(i) = j)
∣∣∣∣∣ ≤ 2M‖K‖∞Π(S)c3hd
almost surely, hence
∣∣∣∣∣R(i)I{A(i) = j} Kh
(
x−X(i))
Qh(x|S)P (A(i) = j) − ER
(i)I{A(i) = j} Kh
(
x−X(i))
Qh(x|S)P (A(i) = j)
∣∣∣∣∣ ≤ 4M‖K‖∞Π(S)c3hd
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almost surely for all x ∈ S ∩ supp(Π). Moreover, (A.4) implies that
Var (η̂j(x;h)) ≤ 2M
2‖K‖∞
n
∫
K
(
x−y
h
)
Q2h(x|S)
dΠS(y) ≤ 2M
2‖K‖∞Π(S)
c3nhd
.
Bernstein’s inequality implies that for all t > 0,
|η̂j(x(i);h)− Eη̂j(x(i);h)| ≤ 2 max
M√2‖K‖∞Π(S)t
c3nhd
, 4
M‖K‖∞t
c3nhd

with probability ≥ 1 − 2e−t. Combined with the union over all 1 ≤ i ≤ N(ε) and noting
that N(ε) ≤ CΠ(S)
εd
, we get that
max
1≤i≤N(ε)
|η̂j(x(i);h)− Eη̂j(x(i);h)| ≤
C max
M√2‖K‖∞Π(S)(t+ d2 log(1/h))
c3nhd
, 2
√
2
M‖K‖∞Π(S)(t+ d2 log(1/h))
c3nhd

with probability ≥ 1− 2e−t. Combined with (A.11) and (A.12), this implies the result.
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